Atorvastatin modulates anti-proliferative and pro-proliferative signals in Her2/neu-positive mammary cancer

Biochemical Pharmacology

Volumn 82, Issue 9, 2011, Pages 1079-1089

  Riganti, Chiara ^a   Pinto, Hedwige ^b   Bolli, Elisabetta ^b   Belisario, Dimas C ^a   Calogero, Raffaele A ^b   Bosia, Amalia ^a   Cavallo, Federica ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Atorvastatin; Her2 positive mammary cancer; NF B; Ras; RhoA

Indexed keywords

ATORVASTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GERANYLGERANYL PYROPHOSPHATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOPRENOID; MEVALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PARTHENOLIDE; PROTEIN KINASE; RAS PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; FEMALE; MAMMARY GLAND; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPTANOIC ACIDS; HYPOLIPIDEMIC AGENTS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE 6; NEOPLASMS, EXPERIMENTAL; NF-KAPPA B; PYRROLES; RAS PROTEINS; RECEPTOR, ERBB-2; RHOA GTP-BINDING PROTEIN; TERPENES;

EID: 80053961800     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.07.079     Document Type: Article

References (43)

1. J.K. Liao Clinical implications for statins pleiotropy Curr Opin Lipidol 16 2005 624 629
2. K.M. Swanson, and R.J. Hohl Anti-cancer therapy: targeting the mevalonate pathway Curr Cancer Drug Targets 6 2006 15 37
3. J.W. Clendening, A. Pandyra, P.C. Boutrosa, S. El Ghamrasni, F. Khosravi, and G.A. Trentin Dysregulation of the mevalonate pathway promotes transformation Proc Natl Acad Sci 107 2010 15051 15056
4. A. Sassano, and L.C. Pltanias Statins in tumor suppression Cancer Lett 260 2008 11 19
5. M.J. Campbell, L.J. Esserman, Y. Zhou, M. Shoemaker, M. Lobo, and E. Barman Breast cancer growth prevention by statins Cancer Res 66 2006 8707 8714 (Pubitemid 44449187)
6. N. Ghosh-Choudhury, C.C. Mandal, N. Ghosh-Choudhury, and G. Ghosh Choudhury Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth Cell Signal 22 2010 749 758
7. J. Klawitter, T. Shokati, V. Moll, U. Christians, and J. Klawitter Effects of lovastatin on breast cancer cells: a proteo-metabonomic study Breast Cancer Res 12 2010 R16
8. J. Dimitroulakos, I.A. Lorimer, and G. Goss Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway Clin Cancer Res 12 2006 4426 4431
9. D.R. Budman, J. Tai, and A. Calabro Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro Breast Cancer Res Treat 104 2007 93 101 (Pubitemid 46976636)
10. R.A. Lubet, D. Boring, V.E. Steele, J.M. Ruppert, M.M. Juliana, and C.J. Grubbs Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis Cancer Prev Res (Phila) 2 2009 161 167
11. F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, and T.G. Cole For the cholesterol and recurrent events trial investigators N Engl J Med 335 1996 1001 1009
12. E.J. Jacobs, C.C. Newton, M.J. Thun, and S.M. Gapstur Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort Cancer Res 71 2011 1763 1771
13. T. Pannellini, G. Forni, and P. Musiani Immunobiology of Her2/Neu transgenic mice Breast Dis 20 2004 33 42
14. R. Merla, Y. Ye, Y. Lin, S. Manickavasagam, M.H. Huang, and R.J. Perez-Polo The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation Am J Physiol Heart Circ Physiol 293 2007 1918 1928
15. G.W. Pearson, and T. Hunter PI-3 kinase activity is necessary for ERK1/2-induced disruption of mammary epithelial architecture Breast Cancer Res 11 2009 R29
16. K. Boggio, G. Nicoletti, E. Di Carlo, F. Cavallo, L. Landuzzi, and C. Melani Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her2/neu transgenic mice J Exp Med 188 1998 589 596 (Pubitemid 28369147)
17. E. Quaglino, C. Mastini, G. Forni, and Cavallo F ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas Curr Protoc Immunol 2008 pp. 20.9.1-20.9.10
18. P. Jones, S. Kafonek, I. Laurora, and D. Hunninghake Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patient with hypercholesterolemia (the curve study) Am J Cardiol 81 1998 582 587 (Pubitemid 28182422)
19. S. Rovero, K. Boggio, E. Di Carlo, A. Amici, E. Quaglino, and P. Porcedda Insertion of the DNA for the 163-171 peptide of IL1beta enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her2/neu transgenic BALB/c mice Gene Ther 8 2001 447 452 (Pubitemid 32266400)
20. S.C. Seifert, and J.J. Lucas Incorporation of mevalonate into dolichol and other isoprenoids during estrogen-induced chick oviduct differentiation Biochim Biophys Acta 962 1988 16 24
21. U. Laufs, and J.K. Liao Targeting Rho in cardiovascular disease Circ Res 87 2000 526 528
22. C. Riganti, S. Orecchia, G.P. Pescarmona, P.G. Betta, D. Ghigo, and A. Bosia Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma Int J Cancer 119 2006 17 27
23. S. Doublier, C. Riganti, C. Voena, C. Costamagna, E. Aldieri, and G. Pescarmona RhoA silencing reverts the resistance to doxorubicin in human colon cancer cells Mol Cancer Res 6 2008 1607 1620
24. F. Cavallo, R. Offringa, S.H. van der Burg, G. Forni, and C.J. Melief Vaccination for treatment and prevention of cancer in animal models Adv Immunol 92 2006 175 213 (Pubitemid 43765801)
25. C. Curcio, E. Di Carlo, R. Clynes, M.J. Smyth, K. Boggio, and E. Quaglino Non redundant roles of antibodies, cytokines, and perforin in the eradication of established Her2/neu carcinomas J Clin Invest 111 2003 1161 1170 (Pubitemid 36519933)
26. R. De Moura Espindola, R.P. Mazzantini, T.P. Ong, A. de Conti, R. Heidor, and F.S. Moreno Geranylgeraniol and β-ionone inhibit hepatic preneoplastic lesions, cell proliferation, total plasma cholesterol and DNA damage during the initial phases of hepatocarcinogenesis, but only the former inhibits NF-(B activation Carcinogenesis 26 2005 1091 1099 (Pubitemid 41214302)
27. J.H. Joo, and A.M. Jetten NF-κB-dependent transcriptional activation in lung carcinoma cells by farnesol involves p65/RelA(Ser276) phosphorylation via the MEK-MSK1 signaling pathway J Biol Chem 283 2008 16391 16399
28. M. Karin, and F.R. Greten NF-κB: linking inflammation and immunity to cancer development and progression Nat Rev Immunol 5 2005 749 759 (Pubitemid 41400849)
29. G. Kallergi, S. Agelaki, A. Kalykaki, C. Stournaras, D. Mavroudis, and V. Georgoulias PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients Breast Cancer Res 10 2008 R80
30. C. Laezza, A.M. Malfitano, M.C. Proto, I. Esposito, P. Gazzerro, and P. Formisano Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cells Endocr Relat Cancer 17 2010 495 503
31. J.K. Liao, and U. Laufs Pleiotropic effects of statins Annu Rev Pharmacol Toxicol 45 2005 89 118 (Pubitemid 40261799)
32. K.S. Ahn, G. Sethi, M.M. Chaturvedi, and B.B. Aggarwal Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-κB ligand through modulation of NF-κB pathway Int J Cancer 123 2008 1733 1740
33. S. Nakata, M. Tsutsui, H. Shimokawa, T. Yamashita, A. Tanimoto, and H. Tasaki Statin treatment upregulates vascular neuronal nitric oxide synthase through Akt/NF-κB pathway Arterioscler Thromb Vasc Biol 27 2007 92 98 (Pubitemid 46360384)
34. Y. Ye, J.D. Martinez, R.J. Perez-Polo, Y. Lin, B.F. Uretsky, and Y. Birnbaum The role of eNOS, iNOS, and NF-κB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin Am J Physiol Heart Circ Physiol 295 2008 H343 H351
35. S. Kotamraju, C.L. Williams, and B. Kalyanaraman Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways Cancer Res 67 2007 7386 7394 (Pubitemid 47206569)
36. R. Rattan, S. Giri, A.K. Singh, and I. Singh RhoA negatively regulates cytokine-mediated inducible nitric oxide synthase expression in brain-derived transformed cell lines: negative regulation of IKKα Free Radic Biol Med 35 2003 1037 1050 (Pubitemid 37315697)
37. S. Araki, K. Dobashi, K. Asayama, and A. Shirahata Simvastatin enhances induction of inducible nitric oxide synthase in 3T3-L1 adipocytes Free Radic Res 41 2007 1028 1034 (Pubitemid 47343407)
38. C. Riganti, S. Doublier, C. Costamagna, E. Aldieri, G. Pescarmona, and D. Ghigo Activation of nuclear factor-κB pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells Mol Pharmacol 74 2008 476 484
39. V.D.-H. Ding, B.T. Sheares, J.D. Bergstrom, M.N. Ponpipom, L.B. Perez, and C.D. Poulter Purification and characterization of recombinant human farnesyl diphosphate synthase expressed in Escherichia coli Biochem J 275 1991 61 65
40. T. Kuzuguchi, Y. Morita, I. Sagami, H. Sagami, and K. Ogura Human geranylgeranyl diphosphate synthase J Biol Chem 274 1999 5888 5894
41. D.L. Pompliano, E. Rands, M.D. Schaber, S.D. Mosser, N.J. Anthony, and J.B. Gibbs Steady-state kinetic mechanism of Ras farnesy1: protein transferase Biochemistry 31 1992 3800 3807
42. F.L. Zhang, J.F. Moomaw, and P.J. Casey Properties and kinetic mechanismo f recombinant mammalian protein geranylgeranyltransferase type I J Biol Chem 269 1994 23465 23470 (Pubitemid 24293544)
43. Y. Cao, J. Luo, and M. Karin IκB kinase α kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells Proc Natl Acad Sci 104 2007 15852 15857 (Pubitemid 350035388)